OGX-427

DRUG7 trials

Conditions

Bladder CancerCastration Resistant Prostate CancerMetastatic Castrate-Resistant Prostate CancerNeoplasmsNon Squamous Non Small Cell Lung CancerPSAPancreatic CancerProstate Cancer

Phase 1

Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer

CompletedNCT00487786

Achieve Life SciencesNeoplasms

Start: 2007-06-30End: 2011-10-31Updated: 2016-01-18

A Study for Treatment of Superficial Bladder Cancer Using OGX-427

NCT00959868

Vancouver Coastal HealthBladder Cancer

Start: 2009-07-31Target: 36Updated: 2012-02-13

Phase 2

OGX-427 in Castration Resistant Prostate Cancer Patients

CompletedNCT01120470

British Columbia Cancer AgencyCastration Resistant Prostate Cancer

Start: 2010-09-30End: 2014-06-30Updated: 2019-02-15

OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

TerminatedNCT01681433

Costantine AlbanyMetastatic Castrate-Resistant Prostate Cancer, Prostate Cancer, PSA

Start: 2012-12-31End: 2017-06-21Updated: 2022-07-11

Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer

CompletedNCT01780545

Noah Hahn, M.D.Bladder Cancer, Urothelial Carcinoma

Start: 2013-04-30End: 2017-10-31Updated: 2022-07-11

Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer

CompletedNCT01829113

SCRI Development Innovations, LLCNon Squamous Non Small Cell Lung Cancer

Start: 2013-07-31End: 2017-04-19Updated: 2018-06-08

Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer

CompletedNCT01844817

SCRI Development Innovations, LLCPancreatic Cancer

Start: 2013-09-30End: 2016-03-31Updated: 2017-05-16

Journal of Clinical Oncology2017-02-2010 citations

Borealis-2: A randomized phase II study of OGX-427 (apatorsen) plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial cancer (mUC) (Hoosier Cancer Research Network GU12-160).

Journal of Clinical Oncology2017-02-208 citations

A randomized, double-blinded, placebo-controlled phase II trial of gemcitabine (gem) plus nab-paclitaxel (nab-P) plus apatorsen (A) or placebo (Pl) in patients (pts) with metastatic pancreatic cancer (mPC): The RAINIER trial.

Journal of Clinical Oncology2016-05-202 citations

The Spruce clinical trial: Double-blind randomized phase II trial of carboplatin and pemetrexed +/- apatorsen in patients with previously untreated stage IV non-squamous non-small-cell lung cancer.

Journal of Clinical Oncology2016-05-201 citations

A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers.

2016-02-1873 citations

RAINIER: A randomized, double-blinded, placebo-controlled phase II trial of gemcitabine (gem) plus nab-paclitaxel (nab-P) combined with apatorsen (A) or placebo (Pl) in patients (pts) with metastatic pancreatic cancer (mPC).

Journal of Clinical Oncology2016-02-014 citations

The Borealis-2 clinical trial: A randomized phase 2 study of OGX-427 (Apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer.

Journal of Clinical Oncology2015-05-202 citations

The Borealis-2 clinical trial: A randomized phase 2 study of OGX-427 (apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer.

Journal of Clinical Oncology2014-05-204 citations

A randomized, double-blinded, placebo-controlled phase II trial of gemcitabine (gem) plus nab-paclitaxel (n-pac) combined with OGX-427 (apatorsen) or placebo in patients (pts) with metastatic pancreatic cancer (mPaCa): The Rainier Trial.

Journal of Clinical Oncology2014-05-201 citations

OGX-427

Sponsors

Conditions

Phase 1

Phase 2

Related Papers